Sarepta Therapeutics Inc., a leader in precision genetic medicine, has announced new equity awards as part of its 2024 Employment Commencement Incentive Plan. On June 30, 2025, the company granted equity awards to 53 newly hired employees. These awards include options to purchase 22,016 shares of Sarepta's common stock and 317,317 restricted stock units (RSUs). The options are priced at $17.10 per share, matching the closing price of Sarepta's stock on the grant date. The options will vest over four years, with an initial 25% vesting after one year and the remainder vesting monthly. Similarly, the RSUs will vest annually over four years, contingent upon continued employment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。